美国胃肠病学会临床实践更新:食管外胃食管反流病的诊断与管理专家综述
美国胃肠病学会(AGA)研究所发布的临床实践更新,基于已发表证据和专家意见,针对疑似食管外反流(EER)患者的临床管理提出10条最佳实践建议,涵盖多学科评估、诊断检测时机、PPI试验策略及替代治疗等,未进行正式系统评价,建议未附证据质量或推荐强度分级。
要点
- 胃肠病学家应询问胃食管反流病(GERD)患者是否存在喉炎、慢性咳嗽、哮喘和牙齿侵蚀等食管外表现。
- 食管外表现常为多因素所致,应考虑多学科方法并参考非消化专科的诊断检测结果。
- 目前无单一诊断工具可确证GER是EER症状的原因,应基于症状、治疗反应、内镜和反流检测的综合临床印象。
核心结论
- 本专家综述基于已发表文献和专家意见提出10条最佳实践建议,用于疑似食管外反流(EER)患者的临床管理,未进行正式系统评价,建议未附正式的证据质量或推荐强度分级。
研究设计与样本
- 美国胃肠病学会(AGA)研究所临床实践更新委员会(CPUC)和AGA理事会委托并批准的专家综述,基于已发表证据和专家意见,非正式系统评价。
主要发现
- 建议1:胃肠病学家应了解GERD的潜在食管外表现,并询问GERD患者是否存在喉炎、慢性咳嗽、哮喘和牙齿侵蚀等以判断GERD是否可能为 contributing factor。
- 建议3:目前无单一诊断工具可确证GER是EER症状的原因,应基于患者症状、对GER治疗的反应、内镜和反流检测结果得出的整体临床印象判断GER对EER症状的贡献。
- 建议5:PPI治疗期间EER表现的症状改善可能源于抑酸以外的作用机制,不应视为GERD的确认。
- 建议6:疑似GERD食管外表现患者经一次PPI试验(最长12周)失败后,应考虑客观检测病理性GER,因不同PPI的额外试验收益低。
- 建议10:对具有明确客观GERD证据的EER患者,在转诊进行抗反流手术前应进行共享决策;但对PPI治疗无反应预示对抗反流手术无反应,应纳入决策过程。
关键数值与推荐
- 建议4:对无典型GERD症状的潜在GERD食管外表现患者,考虑在开始PPI治疗前进行反流诊断检测;对有典型GERD症状者,初始单剂量PPI试验、滴定至每日两次是合理的。
- 建议7:评估反流的初始检测应基于患者临床表现个体化,可包括上消化道内镜和抑酸治疗下的动态反流监测研究。
- 建议8:对已确立客观GERD诊断但大剂量抑酸治疗无反应者,可考虑检测,包括抑酸治疗下的pH-阻抗监测以评估持续酸或非酸反流的作用。
- 建议9:抑酸治疗的替代方法(如生活方式调整、含藻酸盐抗酸剂、外部上食管括约肌压迫装置、认知行为治疗、神经调节剂)可能在EER症状管理中发挥作用。
- 建议2:建立针对食管外(EER)表现的多学科方法的重要考虑,因这些情况常为多因素所致,需要非消化专科的参与;当考虑GER为食管外症状原因时,应参考非消化专科的诊断检测结果(如支气管镜、胸部影像、喉镜等)。
临床怎么用
- 胃肠病学家应主动询问GERD患者的食管外表现(喉炎、慢性咳嗽、哮喘、牙齿侵蚀),以判断GERD是否为 contributing factor。
- 对无典型GERD症状的潜在食管外表现患者,考虑在PPI治疗前进行反流诊断检测;有典型症状者初始单剂量PPI试验合理,可滴定至每日两次。
- 一次PPI试验(最长12周)失败后,应考虑客观检测病理性GER,而非更换不同PPI再试验。
- 对已确立客观GERD诊断但大剂量抑酸无反应者,可考虑抑酸治疗下的pH-阻抗监测。
- 抑酸治疗的替代方法(生活方式调整、含藻酸盐抗酸剂、外部上食管括约肌压迫装置、认知行为治疗、神经调节剂)可能在EER症状管理中发挥作用。
局限性
- 本文档非基于正式系统评价,因此最佳实践建议未附正式的证据质量评级或所呈现考虑因素的推荐强度分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available evidence and expert advice regarding the clinical management of patients with suspected extraesophageal gastroesophageal reflux disease. METHODS: This article provides practical advice based on the available published evidence including that identified from recently published reviews from leading investigators in the field, prospective and population studies, clinical trials, and recent clinical guidelines and technical reviews. This best practice document is not based on a formal systematic review. The best practice advice as presented in this document applies to patients with symptoms or conditions suspected to be related to extraesophageal reflux (EER). This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPUC and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. These Best Practice Advice (BPA) statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these BPA statements do not carry formal ratings of the quality of evidence or strength of the presented considerations. BEST PRACTICE ADVICE 1: Gastroenterologists should be aware of potential extraesophageal manifestations of gastroesophageal reflux disease (GERD) and should inquire about such disorders including laryngitis, chronic cough, asthma, and dental erosions in GERD patients to determine whether GERD may be a contributing factor to these conditions. BEST PRACTICE ADVICE 2: Development of a multidisciplinary approach to extraesophageal (EER) manifestations is an important consideration because the conditions are often multifactorial, requiring input from non-gastroenterology (GI) specialties. Results from diagnostic testing (ie, bronchoscopy, thoracic imaging, laryngoscopy, etc) from non-GI disciplines should be taken into consideration when gastroesophageal reflux (GER) is considered as a cause for extraesophageal symptoms. BEST PRACTICE ADVICE 3: Currently, there is no single diagnostic tool that can conclusively identify GER as the cause of EER symptoms. Determination of the contribution of GER to EER symptoms should be based on the global clinical impression derived from patients' symptoms, response to GER therapy, and results of endoscopy and reflux testing. BEST PRACTICE ADVICE 4: Consideration should be given toward diagnostic testing for reflux before initiation of proton pump inhibitor (PPI) therapy in patients with potential extraesophageal manifestations of GERD, but without typical GERD symptoms. Initial single-dose PPI trial, titrating up to twice daily in those with typical GERD symptoms, is reasonable. BEST PRACTICE ADVICE 5: Symptom improvement of EER manifestations while on PPI therapy may result from mechanisms of action other than acid suppression and should not be regarded as confirmation for GERD. BEST PRACTICE ADVICE 6: In patients with suspected extraesophageal manifestation of GERD who have failed one trial (up to 12 weeks) of PPI therapy, one should consider objective testing for pathologic GER, because additional trials of different PPIs are low yield. BEST PRACTICE ADVICE 7: Initial testing to evaluate for reflux should be tailored to patients' clinical presentation and can include upper endoscopy and ambulatory reflux monitoring studies of acid suppressive therapy. BEST PRACTICE ADVICE 8: Testing can be considered for those with an established objective diagnosis of GERD who do not respond to high doses of acid suppression. Testing can include pH-impedance monitoring while on acid suppression to evaluate the role of ongoing acid or non-acid reflux. BEST PRACTICE ADVICE 9: Alternative treatment methods to acid suppressive therapy (eg, lifestyle modifications, alginate-containing antacids, external upper esophageal sphincter compression device, cognitive-behavioral therapy, neuromodulators) may serve a role in management of EER symptoms. BEST PRACTICE ADVICE 10: Shared decision-making should be performed before referral for anti-reflux surgery for EER when the patient has clear, objectively defined evidence of GERD. However, a lack of response to PPI therapy predicts lack of response to anti-reflux surgery and should be incorporated into the decision process.
引用
- Chen JW, Vela MF, Peterson KA, et al. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review. Clin Gastroenterol Hepatol. 2023. PMID: 37061897. doi:10.1016/j.cgh.2023.01.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。